Low Dose IL-2 Improves Salivary Gland Function in Sjögren’s Mouse Model
A low dose treatment of interleukin-2 (IL-2), an immune signaling protein, improved salivary gland function in a Sjögren’s syndrome mouse model, but it didn’t reverse immune-mediated structural damage to the glands, a study showed. Although IL-2 may improve salivary gland function in Sjögren’s, combining it with other immunomodulatory therapies…